<DOC>
	<DOCNO>NCT00520234</DOCNO>
	<brief_summary>Adults admit intensive care unit risk variety complication . Infections due fungus call candida particular concern . The study test possibility caspofungin , new therapy fungal infection , successfully reduce rate candida infection subject risk . It also test caspofungin useful treat subject disease diagnose use new blood test perform twice weekly , permit early diagnosis current practice standard .</brief_summary>
	<brief_title>Randomized Study Caspofungin Prophylaxis Followed Pre-emptive Therapy Invasive Candidiasis Intensive Care Unit ( ICU )</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Invasive</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Nonpregnant &gt; 18 yrs age Subjects admit ICU precede 3 day expect stay ICU least another 48 hours.Subjects enrol day 35 ICU admission . Subjects meet clinical prediction rule Subjects allergy/intolerance caspofungin echinocandin analog absolute neutrophil count &lt; 500/mm3 study entry likely develop count therapy acquire immunodeficiency syndrome , aplastic anemia chronic granulomatous disease moderate severe hepatic insufficiency subject pregnant lactate unlikely survive &lt; 24 hour subject receive systemic antifungal therapy within 10 day prior study entry Documented active proven probable invasive fungal infection upon enrollment previously enrol study Currently another investigational agent receive investigational agent within 10 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Candida</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>High risk adult</keyword>
	<keyword>Intensive care unit ( ICU )</keyword>
</DOC>